Ubs Group Ag Atea Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 78,391 shares of AVIR stock, worth $250,067. This represents 0.0% of its overall portfolio holdings.

Number of Shares

78,391

Previous 71,579 9.52%

Holding current value

$250,067

Previous $236,000 11.02%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.17 - $4.02 $21,594 - $27,384	6,812 Added 9.52%	78,391 $262,000
Q2 2024 Aug 13, 2024	SELL	$3.31 - $4.04 $107,545 - $131,263	-32,491 Reduced 31.22%	71,579 $236,000
Q1 2024 May 13, 2024	SELL	$3.09 - $4.56 $11,049 - $16,306	-3,576 Reduced 3.32%	104,070 $420,000
Q4 2023 Feb 09, 2024	BUY	$2.8 - $3.35 $141,694 - $169,526	50,605 Added 88.72%	107,646 $328,000
Q3 2023 Nov 09, 2023	SELL	$3.0 - $3.79 $125,469 - $158,509	-41,823 Reduced 42.3%	57,041 $171,000
Q2 2023 Aug 11, 2023	BUY	$3.21 - $5.06 $147,823 - $233,018	46,051 Added 87.2%	98,864 $369,000
Q1 2023 May 12, 2023	SELL	$3.0 - $4.97 $67,266 - $111,437	-22,422 Reduced 29.8%	52,813 $176,000
Q4 2022 Feb 08, 2023	BUY	$4.35 - $6.17 $260,208 - $369,077	59,818 Added 388.0%	75,235 $361,000
Q3 2022 Nov 10, 2022	BUY	$5.49 - $8.79 $22,871 - $36,619	4,166 Added 37.03%	15,417 $88,000
Q2 2022 Aug 10, 2022	SELL	$5.33 - $8.18 $94,628 - $145,227	-17,754 Reduced 61.21%	11,251 $80,000
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $416,438 - $695,830	-75,716 Reduced 72.3%	29,005 $209,000
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $314,730 - $1.83 Million	41,034 Added 64.43%	104,721 $935,000
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $13 Million - $21.4 Million	-611,422 Reduced 90.57%	63,687 $2.23 Million
Q2 2021 Aug 13, 2021	BUY	$19.22 - $59.08 $12.9 Million - $39.7 Million	671,483 Added 18518.56%	675,109 $14.5 Million
Q1 2021 May 12, 2021	SELL	$41.42 - $88.44 $287,620 - $614,127	-6,944 Reduced 65.7%	3,626 $224,000
Q4 2020 Feb 11, 2021	BUY	$26.36 - $41.78 $278,625 - $441,614	10,570 New	10,570 $442,000

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $266M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account